SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Sund Malin) "

Sökning: WFRF:(Sund Malin)

  • Resultat 1-10 av 251
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Jansson, Malin, et al. (författare)
  • Expression and Circulating Levels of Perlecan in Breast Cancer : Implications for Oestrogen Dependent Stromal Remodeling
  • 2020
  • Ingår i: Journal of mammary gland biology and neoplasia. - : Springer Science and Business Media LLC. - 1083-3021 .- 1573-7039. ; 25, s. 69-77
  • Tidskriftsartikel (refereegranskat)abstract
    • Localised breast cancer can be cured by surgery and adjuvant treatments, but mortality remains high as some tumours metastasize early. Perlecan is a basement membrane (BM) protein involved in tumour development and progression. Here, mRNA and protein expression of perlecan, and mRNA expression of matrix degrading enzymes were studied in normal breast and invasive breast cancer, and correlated to prognostic risk factors, in particular oestrogen status. Moreover, plasma levels of perlecan were measured in patients with breast cancer and compared with controls. mRNA data was extracted from the Cancer Genome Atlas database. Perlecan protein expression was visualized using immunofluorescence and plasma levels measured by ELISA assay. Perlecan mRNA levels were twice as high in normal breast compared with breast cancer tissue. A strong correlation was found between mRNA expression of perlecan and several matrix-degrading enzymes in oestrogen receptor positive (ER+) tumours. Perlecan protein was localized to both epithelial and vascular BMs, but absent in the stroma in normal breast. In breast cancer, the expression of perlecan in epithelial BM was fragmented or completely lost, with a marked upregulation of perlecan expression in the stroma. Significantly higher levels of perlecan were found in plasma of ER+ patients when compared with ER- patients. This study shows that perlecan expression and degradation in breast cancer may be linked to the ER status of the tumour.
  •  
4.
  • Jansson, Malin, et al. (författare)
  • MiR-155-mediated loss of C/EBP beta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer
  • 2013
  • Ingår i: Oncogene. - : Nature Publishing Group. - 0950-9232 .- 1476-5594. ; 32:50, s. 5614-5624
  • Tidskriftsartikel (refereegranskat)abstract
    • During breast cancer progression, transforming growth factor-beta (TGF-beta) switches from acting as a growth inhibitor to become a major promoter of epithelial-mesenchymal transition (EMT), invasion and metastasis. However, the mechanisms involved in this switch are not clear. We found that loss of CCAAT-enhancer binding protein beta (C/EBP beta), a differentiation factor for the mammary epithelium, was associated with signs of EMT in triple-negative human breast cancer, and in invasive areas of mammary tumors in MMTV-PyMT mice. Using an established model of TGF-beta-induced EMT in mouse mammary gland epithelial cells, we discovered that C/EBP beta was repressed during EMT by miR-155, an oncomiR in breast cancer. Depletion of C/EBP beta potentiated the TGF-beta response towards EMT, and contributed to evasion of the growth inhibitory response to TGF-beta. Furthermore, loss of C/EBP beta enhanced invasion and metastatic dissemination of the mouse mammary tumor cells to the lungs after subcutaneous injection into mice. The mechanism by which loss of C/EBP beta promoted the TGF-beta response towards EMT, invasion and metastasis, was traced to a previously uncharacterized role of C/EBP beta as a transcriptional activator of genes encoding the epithelial junction proteins E-cadherin and coxsackie virus and adenovirus receptor. The results identify miR-155-mediated loss of C/EBP beta as a mechanism, which promotes breast cancer progression by shifting the TGF-beta response from growth inhibition to EMT, invasion and metastasis.
  •  
5.
  • Jansson, Malin, et al. (författare)
  • Prognostic Value of Stromal Type IV Collagen Expression in Small Invasive Breast Cancers
  • 2022
  • Ingår i: Frontiers in Molecular Biosciences. - : Frontiers Media SA. - 2296-889X. ; 9
  • Tidskriftsartikel (refereegranskat)abstract
    • Breast cancer is the most common cause of cancer death among women worldwide. Localized breast cancer can be cured by surgery and adjuvant therapy, but mortality remains high for tumors that metastasize early. Type IV collagen is a basement membrane protein, and breach of this extracellular matrix structure is the first step of cancer invasion. Type IV collagen is found in the stroma of many cancers, but its role in tumor biology is unclear. Here, expression of type IV collagen in the stroma of small breast cancers was analyzed, correlated to clinically used prognostic biomarkers and patient survival. The findings were further validated in an independent gene expression data cohort. Tissue samples from 1,379 women with in situ and small invasive breast cancers (<= 15 mm) diagnosed in 1986-2004 were included. Primary tumor tissue was collected into tissue microarrays. Type IV collagen expression in tissues was visualized using immunohistochemistry. Gene expression data was extracted from the Cancer Genome Atlas database. Out of 1,379 women, 856 had an invasive breast cancer and type IV collagen staining was available for 714 patients. In Kaplan-Meier analysis high type IV collagen expression was significantly associated (p = 0.026) with poorer breast cancer specific survival. There was no correlation of type IV collagen expression to clinically used prognostic biomarkers. High type IV collagen expression was clearly associated to distant metastasis (p = 0.002). In an external validation cohort (n = 1,104), high type IV collagen mRNA expression was significantly (p = 0.041) associated with poorer overall survival, with overexpression of type IV collagen mRNA in metastatic tissue. Stromal type IV collagen expression in the primary tumor correlates to poor breast cancer specific survival most likely due to a higher risk of developing distant metastasis. This ECM protein may function as biomarker to predict the risk of future metastatic disease in patients with breast cancers.
  •  
6.
  •  
7.
  • Jansson, Malin, 1978- (författare)
  • The role of stroma-derived substances in breast cancer progression and their function as tumour markers
  • 2022
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Background: In 2020, more than 2,260,000 women were diagnosed with breast cancer. Most patients are cured with surgery and adjuvant treatment, but despite that, approximately 700,000 women die of the disease every year. The historical focus on breast cancer progression has been on the malignant epithelial cell. However, cancer cells do not grow in isolation. In recent years, the importance of the tumour microenvironment in cancer progression has been highlighted. Perlecan and type IV collagen are basement membrane (BM) proteins in the normal mammary gland, and type I collagen is the main fibrillar collagen in the interstitial extracellular matrix (ECM). In cancer development, perlecan and type IV collagen have multifunctional roles and when degraded from the BM, bioactive substances and other fragments are released in the circulation. Significant ECM changes also occur that lead to an accumulation of fibrillar collagens. Given their abundance in the ECM; perlecan, type IV and type I collagen are of interest for breast cancer progression and may be of importance as new biomarkers to monitor disease, predict patient outcome and the treatment effect.Aim: In this thesis, the protein and mRNA expression of perlecan, type IV and I collagen in breast cancer tissue is studied. The aim is to characterize the expression pattern of these proteins in breast cancer tissue and to see whether there is a correlation to known prognostic biomarkers and to the patient prognosis. Moreover, to evaluate circulating perlecan and type IV collagen as diagnostic and prognostic biomarkers in breast cancer patients.Methods: In this thesis project, eight different patient cohorts were used. In freshly frozen normal breast and breast cancer tissue, perlecan protein expression was visualized using immunofluorescence. Type IV and I collagen protein expression were studied with immunohistochemistry in formalin-fixed, paraffin embedded primary breast cancer tissue, and type IV collagen in metastatic breast cancer tissue. For gene expression analysis, mRNA and clinicopathological data were extracted from the Cancer Genome Atlas and cBioportal database. Circulating plasma levels of perlecan were analysed in breast cancer patients and controls, circulating levels of CA15-3 and type IV collagen in patients with primary and metastatic breast cancer as well as controls. Perlecan and type IV collagen were measured with ELISA assays, and CA15-3 were using an electrochemiluminescence immunoassay.Results: In breast cancer tissue, perlecan and type IV collagen protein expression in the epithelial BM was fragmented or completely lost, and perlecan and type IV collagen was expressed to varying extent in the tumour stroma. The mRNA analysis confirmed that type IV collagen mRNA was expressed in primary breast cancer tissue and highly expressed in metastatic tissue. Type I collagen was mostly highly expressed in the tumour stroma. Low type I collagen protein and mRNA expression correlated with biomarkers for aggressive breast cancer, but no effect on survival could be seen. Among patients receiving chemotherapy, low stromal type I collagen protein expression was associated with better survival compared to high expression, even after adjusting for other relevant factors. There was no correlation of perlecan or type IV collagen protein expression to clinically used prognostic biomarkers, but an oestrogen receptor dependent correlation between mRNA expression of perlecan and several matrix-degrading enzymes were found. Survival analysis showed that high stromal type IV collagen protein and mRNA expression in the primary tumour was significantly associated with a poorer survival, and high protein expression with a risk of developing distant metastasis. Metastatic breast cancer patients had higher levels of circulating type IV collagen compared to healthy controls and patients with primary breast cancer. High circulating type IV collagen levels correlated with poorer survival in metastatic breast cancer patients, and was superior to CA15-3 at detecting metastatic breast cancer.Conclusions: The protein expression pattern of perlecan, type IV collagen and type I collagen become abnormal during breast cancer development. Stromal type IV collagen protein and mRNA in the primary tumour correlates to poorer prognosis, most likely due to a higher risk of developing metastatic disease. Circulating type IV collagen can function as a biomarker for detecting metastatic disease in patients with primary breast cancer and is prognostic in patients with metastatic breast cancer. Low stromal type I collagen is a marker for an aggressive breast cancer disease and can predict chemotherapy response.
  •  
8.
  •  
9.
  • Pang, M-F, et al. (författare)
  • TGF-beta 1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis
  • 2016
  • Ingår i: Oncogene. - : Nature Publishing Group. - 0950-9232 .- 1476-5594. ; 35:6, s. 748-760
  • Tidskriftsartikel (refereegranskat)abstract
    • Tumor cells frequently disseminate through the lymphatic system during metastatic spread of breast cancer and many other types of cancer. Yet it is not clear how tumor cells make their way into the lymphatic system and how they choose between lymphatic and blood vessels for migration. Here we report that mammary tumor cells undergoing epithelial-mesenchymal transition (EMT) in response to transforming growth factor-beta (TGF-beta 1) become activated for targeted migration through the lymphatic system, similar to dendritic cells (DCs) during inflammation. EMT cells preferentially migrated toward lymphatic vessels compared with blood vessels, both in vivo and in 3D cultures. A mechanism of this targeted migration was traced to the capacity of TGF-beta 1 to promote CCR7/CCL21-mediated crosstalk between tumor cells and lymphatic endothelial cells. On one hand, TGF-beta 1 promoted CCR7 expression in EMT cells through p38 MAP kinase-mediated activation of the JunB transcription factor. Blockade of CCR7, or treatment with a p38 MAP kinase inhibitor, reduced lymphatic dissemination of EMT cells in syngeneic mice. On the other hand, TGF-beta 1 promoted CCL21 expression in lymphatic endothelial cells. CCL21 acted in a paracrine fashion to mediate chemotactic migration of EMT cells toward lymphatic endothelial cells. The results identify TGF-beta 1-induced EMT as a mechanism, which activates tumor cells for targeted, DC-like migration through the lymphatic system. Furthermore, it suggests that p38 MAP kinase inhibition may be a useful strategy to inhibit EMT and lymphogenic spread of tumor cells.
  •  
10.
  • Rask, Gunilla, et al. (författare)
  • Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study
  • 2022
  • Ingår i: Breast Cancer Research and Treatment. - : Springer Science and Business Media LLC. - 0167-6806 .- 1573-7217. ; 195:3, s. 367-377
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC). Methods Tissue samples from 445 women with node-negative BC <= 15 mm, treated in 1986-2004, were classified into surrogate molecular subtypes [Luminal A-like, Luminal B-like (HER2-), HER2-positive, and triple negative breast cancer (TNBC)]. Information on treatment, recurrences, and survival were gathered from medical records. Results Tumour subtype was not associated with overall survival (OS). Luminal B-like (HER2-) and TNBC were associated with higher incidence of distant metastasis at 20 years (Hazard ratio (HR) 2.26; 95% CI 1.08-4.75 and HR 3.24; 95% CI 1.17-9.00, respectively). Luminal B-like (HER2-) and TNBC patients also had worse breast cancer-specific survival (BCSS), although not statistically significant (HR 1.53; 95% CI 0.70-3.33 and HR 1.89; 95% CI 0.60-5.93, respectively). HER2-positive BC was not associated with poor outcome despite no patient receiving HER2-targeted therapy, with most of these tumours being ER+. Conclusions Stage 1 TNBC or Luminal B-like (HER2-) tumours behave more aggressively. Women with HER2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 251
Typ av publikation
tidskriftsartikel (216)
doktorsavhandling (16)
annan publikation (11)
forskningsöversikt (4)
konferensbidrag (2)
bokkapitel (2)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (214)
övrigt vetenskapligt/konstnärligt (35)
populärvet., debatt m.m. (2)
Författare/redaktör
Sund, Malin (174)
Riboli, Elio (65)
Sund, Malin, 1972- (60)
Overvad, Kim (59)
Trichopoulou, Antoni ... (59)
Khaw, Kay-Tee (58)
visa fler...
Tumino, Rosario (57)
Kaaks, Rudolf (56)
Weiderpass, Elisabet ... (56)
Boeing, Heiner (50)
Boutron-Ruault, Mari ... (45)
Panico, Salvatore (45)
Travis, Ruth C (40)
Tjønneland, Anne (38)
Palli, Domenico (37)
Trichopoulos, Dimitr ... (37)
Dossus, Laure (34)
Sánchez, Maria-José (32)
Duell, Eric J. (32)
Ardanaz, Eva (31)
Wareham, Nick (30)
Bueno-de-Mesquita, H ... (30)
Vineis, Paolo (29)
Tjonneland, Anne (29)
Clavel-Chapelon, Fra ... (28)
Jenab, Mazda (28)
Amiano, Pilar (27)
Peeters, Petra H. M. (27)
Olsen, Anja (26)
Romieu, Isabelle (26)
Chirlaque, Maria-Dol ... (25)
Key, Timothy J (25)
Lagiou, Pagona (25)
Peeters, Petra H (24)
Skeie, Guri (24)
Canzian, Federico (24)
Barricarte, Aurelio (22)
Lund, Eiliv (21)
Masala, Giovanna (20)
Sacerdote, Carlotta (20)
Rinaldi, Sabina (20)
Dorronsoro, Miren (20)
Wärnberg, Fredrik (19)
Krogh, Vittorio (18)
Mattiello, Amalia (18)
Visvanathan, Kala (17)
Kraft, Peter (17)
Giles, Graham G (16)
Agnoli, Claudia (16)
Bamia, Christina (16)
visa färre...
Lärosäte
Umeå universitet (224)
Lunds universitet (53)
Karolinska Institutet (43)
Uppsala universitet (32)
Göteborgs universitet (27)
Örebro universitet (6)
visa fler...
Linköpings universitet (3)
Stockholms universitet (1)
Malmö universitet (1)
Mittuniversitetet (1)
Högskolan i Skövde (1)
Sveriges Lantbruksuniversitet (1)
Röda Korsets Högskola (1)
visa färre...
Språk
Engelska (249)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (214)
Naturvetenskap (5)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy